Procaps Group/PROC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Procaps Group

Procaps Group SA is a Luxembourg-based healthcare and pharmaceutical company. The Company develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. It operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.

Ticker

PROC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

Headquarters

Luxembourg, Luxembourg

Employees

5,500

Procaps Group Metrics

BasicAdvanced
$311M
Market cap
5.30
P/E ratio
$0.52
EPS
0.17
Beta
-
Dividend rate
$311M
0.17
$4.95
$1.95
0.16
1.47
0.986
560.306
736.099
14.101
10.77%
350.21%
19.01%
5.299
0.752
7.906
9.142
8.07%

What the Analysts think about Procaps Group

Analyst Ratings

Majority rating from 2 analysts.
Buy

Procaps Group Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
6.84% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$118M
7.64%
Net income
$8.1M
-69.89%
Profit margin
6.84%
-72.02%

Procaps Group Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 60.00%
QuarterlyAnnual
Q4 22
Q1 23
Q3 23
Q4 23
Actual
$0.10
$0.07
$0.08
-
Expected
$0.01
-$0.04
$0.05
$0.09
Surprise
900.00%
-275.00%
60.00%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Procaps Group stock?

Procaps Group (PROC) has a market cap of $311M as of June 24, 2024.

What is the P/E ratio for Procaps Group stock?

The price to earnings (P/E) ratio for Procaps Group (PROC) stock is 5.3 as of June 24, 2024.

Does Procaps Group stock pay dividends?

No, Procaps Group (PROC) stock does not pay dividends to its shareholders as of June 24, 2024.

When is the next Procaps Group dividend payment date?

Procaps Group (PROC) stock does not pay dividends to its shareholders.

What is the beta indicator for Procaps Group?

Procaps Group (PROC) has a beta rating of 0.17. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Procaps Group stock price target?

The target price for Procaps Group (PROC) stock is $4.75, which is NaN% below the current price of $. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Procaps Group stock

Buy or sell Procaps Group stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing